



Research Article

www.ijrap.net



A CLINICAL STUDY ON EFFECT OF AMALAKI (INDIAN GOOSEBERRY) AS FOOD SUPPLEMENT IN DYSLIPIDEMIA

M. B. Kavita^{1*}, Mallika KJ², Poornima B³

¹Research Student and Associate Professor, Department of Swasthavritta, SDM College of Ayurveda and Hospital, Tanniruhalla, B. M. Road, Hassan, Karnataka State, India

²Professor, Department of Samhita & Siddhanta, SDM College of Ayurveda and Hospital, Tanniruhalla, B. M. Road, Hassan, Karnataka, India

³Associate Professor, Department of Dravyaguna, SDM Institute of Ayurveda, Anchepalya, Kumbalgodu, Bengaluru, Karnataka, India

Received on: 04/05/16 Revised on: 27/05/16 Accepted on: 18/06/16

*Corresponding author

E-mail: mbkhsn77@gmail.com

DOI: 10.7897/2277-4343.074134

ABSTRACT

Dyslipidemia is a condition which is an iceberg. Amalaki (*Embelica officinalis* Garten) is a fruit listed under wholesome and daily consumables in Ayurveda classics with its components said to improve lipid metabolism and prevent oxidative stress. This directed towards Amalaki to be used as food supplement in dyslipidemia. An open randomized study involving diagnosed cases of dyslipidemia with or without symptoms. The study involved subjects with age group of 20 to 70 years irrespective of the gender. The diagnostic criteria were as mentioned by American Heart Association. Study involved two groups. Amalaki group (study group) was administered with 12 grams of Amalaki choorna to be consumed with major food of the day. The Diet group (control group) was advised minimal dietary manipulations. Study duration was 2 months and biochemical analysis of lipid was done before treatment and after 2 months. Data was analysed with suitable statistical methods. Out of 116 subjects, 102 subjects completed the study. Majority (69%) had Kapha-Vata Prakriti. Majority had overweight and with waist hip ratio increased. When tested between the group, Amalaki group showed a better results in TC (p value 0.014), HDL-C (p value 0.001) and triglycerides (p value <0.002). The result of LDL between group was found to be not significant with p value 0.898 (>0.05). The study concludes that administration of Amalaki Choorna (powder of *Embelica officinalis* Garten) is a possible food supplement of choice that manages dyslipidemia significantly without causing any adverse effects.

Key words: Ayurveda, Amalaki, *Embelica officinalis* Garten Food Supplement, Lipids, dyslipidemia

INTRODUCTION

Dyslipidemia is a condition which is mostly an iceberg. There are many studies which highlighted the prevalence in types of dyslipidemia in India. An ICMR survey¹ report published in 2014 concluded that over 79% of general adult population covered in the survey has abnormality in at least one of the lipid parameters with no urban rural difference. This calls for an urgent interventional strategy which can be applied in mass, easily adaptable, natural and feasible.

The US Food and Drug Administration defines food supplement² as a product intended for ingestion that contains a "dietary ingredient" intended to add further nutritional value to (supplement) the diet. A "dietary ingredient" may be one, or any combination, of a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by people to supplement the diet by increasing the total dietary intake or a concentrate, metabolite, constituent, or extract. Dietary supplements may be found in many forms such as tablets, capsules, soft gels, gel caps, liquids, or powders. Some dietary supplements can help ensure to get an adequate dietary intake of essential nutrients; others may help you reduce your risk of disease.

Amalaki (*Embelica officinalis* Garten) is a fruit that is rich in nutrients acting as antioxidants³; flavonoids and tannins⁴ protect the nutrients in Amalaki from being destroyed on processing. This is considered to be a rejuvenator⁵ as well as a fruit for daily

consumption⁶ in classics of Ayurveda. This can be consumed any time in relation to food i.e., before, along with or after food⁷. Amalaki is a fruit that is available in most part of India either as fresh fruit or in powder form. This is a fruit that is easily accepted by the population for consumption, natural and cost effective. All the above facts directed towards Amalaki to be used as food supplement in dyslipidemia.

MATERIALS AND METHODS

An open randomized study with Institutional Ethical clearance number SDM/IEC/02/2009-10 dated 16.03.2010 involving diagnosed cases of dyslipidemia with or without symptoms visiting SDM College of Ayurveda and Hospital, Hassan. The study involved subjects with age group of 20 to 70 years irrespective of the gender. Established cases of cardiovascular diseases, diabetes mellitus, hypothyroidism and those on drugs affecting the lipid levels like OC pills, statins etc were excluded from the study. The diagnostic criteria for dyslipidemia as mentioned by American Heart Association⁸ was considered for the study i.e., Total cholesterol <200 mg / dl; LDL <100/dl; HDL for men <40 mg/dl and females <50mg/dl; Triglycerides <150 mg/dl and VLDL <35 mg/dl. Clinical examinations included anthropometric examination and examination of vitals like BP, pulse, temperature. The subjects selected for study were alternatively divided in two groups where the study group (Amalaki group) was administered with 12 grams of Amalaki choorna to be consumed with major food of the day; the control group (Diet group) which was advised minimal dietary

manipulations. Both groups were studied for a period of 2 months and biochemical analysis of lipid was done before treatment and after 2 months. Because the purpose of the study is to evaluate the Amalaki churna as food supplement which can be taken on daily basis as a part of food, follow up after treatment was not done for those who completed the course of study. They were asked to continue consume Amalaki on daily basis if possible.

OBSERVATIONS AND RESULTS

A total of 116 subjects volunteered to participate in study who fulfilled both diagnostic and inclusion criteria by giving a written consent to be a part of study. A total of 102 subjects completed the study. The Amalaki group (study group) involved a total of 57 subjects among which 52 completed the intervention period; diet manipulation group had 59 subjects out of which a total of 50 completed study period (Table 1). Study had 50% of both males and females which indicating equal or nearly equal gender distribution in dyslipidemia (Table 2). The condition was dominated by subjects in age group 30 to 39 years (44%) followed by age group 20 to 29 years (34.5 %) indicating the shift of condition from older age group to younger age group (Table 3). The nature of work based on physical activity involved majority of sedentary workers (75.9%) showing sedentary life as a risk factor for dyslipidemia (Table 4). Majority (69%) of subjects were with Kapha-Vata prakriti (Table No. 5). The condition dyslipidemia involves Kapha and Vata dosha and the subjects with Kapha-Vata prakriti will always be at risk for diseases/conditions predominated by such dosha.

Prevalence of no symptoms (Table 6) and the subjects presented with very few clinical signs i.e., Xanthelasma palpebrum in one; Xanthomata of elbow in one and transient ischemic attack in two subjects; Majority of them presented no symptoms. This

indicates that dyslipidemia is an iceberg condition. The anthropometric examinations viz., body mass index (Table 7) majority of overweight (51.7%) and obesity (31.9%); waist hip ratio (Table 8) was increased in a total of 90.6% subjects among whom 46.6% were males and 44% were females. These findings position them as risk factors for dyslipidemia⁹ Among the lipids in lipid profile (Table 9), the low density lipoprotein abnormality was seen in majority of the subjects (84.5%) followed by abnormality of triglycerides (69%).

There was no trouble in majority of subjects in consuming 12 grams of Amalaki powder as it was used along the major food of the day. No adverse reactions were reported in both groups. Four subjects reported relief from constipation and two had improvement in symptoms of gastritis in Amalaki group. Amalaki group showed a highly significant results in the BMI, Total cholesterol, LDL-C, HDL-C, VLDL-C and Triglycerides with P value <0.001. The Dietary intervention group showed a highly significant results in the BMI, Total cholesterol, LDL-C and Triglycerides with P value <0.001 while HDL-C and VLDL-C showed significant results (p value <0.05) with p values 0.004 and 0.006 respectively. When tested between the group, Amalaki group showed a highly significant results in the BMI, Total cholesterol, LDL-C, HDL-C, VLDL-C and Triglycerides with P value <0.001. The Dietary intervention group showed a highly significant results in the BMI, Total cholesterol, LDL-C and Triglycerides with P value <0.001 while HDL-C and VLDL-C showed significant results (p value <0.05) with p values 0.004 and 0.006 respectively. When tested between the group, Amalaki group showed a better results in TC (p value 0.014), HDL-C (p value 0.001) and triglycerides (p value <0.002). Diet group was better with mean difference -0.6262 in BMI (p value <0.001). The result of LDL between group was found to be not significant with p value 0.898 (>0.05).

Table 1: Clinical Group

| | Included for study | Completed | Dropouts |
|-----------------|--------------------|-----------|----------|
| Amalaki Choorna | 57 | 52 | 05 |
| Diet control | 59 | 50 | 09 |
| Total | 116 | 102 | 14 |

Table 2: Gender

| | Frequency | Percent |
|-------|-----------|---------|
| Men | 58 | 50 |
| Women | 58 | 50 |
| Total | 116 | 100 |

Table 3: Age Group

| | Frequency | Percent |
|---------------|-----------|---------|
| 20 - 29 years | 40 | 34.5 |
| 30-39 years | 51 | 44 |
| 40 - 49 years | 21 | 18.1 |
| 50-59 Years | 4 | 3.4 |
| Total | 116 | 100 |

Table 4: Nature of Work

| | Frequency | Percent |
|------------------|-----------|---------|
| Sedentary worker | 88 | 75.9 |
| Moderate worker | 28 | 24.1 |
| Total | 116 | 100 |

Table 5: Prakriti

| | Frequency | Percent |
|-------------|-----------|---------|
| Kapha-Vata | 80 | 69 |
| Kapha-Pitta | 15 | 12.9 |
| Pitta-Vata | 2 | 1.7 |
| Pitta-Kapha | 2 | 1.7 |
| Vata-Pitta | 2 | 1.7 |
| Vata-Kapha | 15 | 12.9 |
| Total | 116 | 100 |

Table 6: Symptoms on 0th Day

| | | Frequency | Percent |
|---|---------|-----------|---------|
| Dizziness | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Impairment of balance | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Difficulty in speaking | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Problem with vision | Absent | 111 | 95.7 |
| | Present | 5 | 4.3 |
| Chest pain | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Calf pain | Absent | 113 | 97.4 |
| | Present | 3 | 2.6 |
| Yellowish patches underneath skin of eyelid | Absent | 115 | 99.1 |
| | Present | 1 | 0.9 |
| Soft yellowish mass in the palms/knees/elbows | Absent | 115 | 99.1 |
| | Present | 1 | 0.9 |
| Tiredness (Dourbalya) | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Bad smell from body (dourgandhya) | Absent | 109 | 94 |
| | Present | 7 | 6 |
| Minimal/no sweat (Swedabadha) | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Excessive hunger (Atikshudha) | Absent | 3 | 2.6 |
| | Present | 113 | 97.4 |
| Excessive thirst (Ati pipasa) | Absent | 116 | 100 |
| | Present | 0 | 0 |
| Lethargy (Javoparodha) | Absent | 103 | 88.8 |
| | Present | 13 | 11.2 |

Table 7: Body Mass Index

| | Frequency | Percent |
|---------------|-----------|---------|
| normal weight | 19 | 16.4 |
| over weight | 60 | 51.7 |
| obese | 37 | 31.9 |
| Total | 116 | 100 |

Table 8: Waist Hip Ratio

| | | Frequency | Percent |
|----------------------------------|-----------|-----------|---------|
| Men | Normal* | 04 | 3.4 |
| | Increased | 54 | 46.6 |
| Women | Normal* | 07 | 6.0 |
| | Increased | 51 | 44.0 |
| *Normal - Men: <0.9; Women: <0.8 | | | |

Table 9: Lipid Profile

| Lipid Varieties | | Frequency | Percent |
|--|-----------|-----------|---------|
| Total Cholesterol | Normal | 49 | 42.2 |
| | increased | 67 | 57.8 |
| Low Density Lipoprotein - Cholesterol | Normal | 18 | 15.5 |
| | Increased | 98 | 84.5 |
| High Density Lipoprotein - Cholesterol | Normal | 51 | 44 |
| | Decreased | 65 | 56 |
| Triglycerides | Normal | 36 | 31 |
| | Increased | 80 | 69 |
| Very Low Density Lipoprotein - Cholesterol | Normal | 60 | 51.7 |
| | Increased | 56 | 48.3 |

Table 10: Paired Samples Test (Amalaki Group)

| | Paired Differences | | | | | t | df | Sig. (2-tailed) |
|-------------------------------------|--------------------|----------------|-----------------|---|---------|--------|----|-----------------|
| | Mean | Std. Deviation | Std. Error Mean | 95% Confidence Interval of the Difference | | | | |
| | | | | Lower | Upper | | | |
| BMI BT - BMI AT | .14692 | .21910 | .03038 | .08592 | .20792 | 4.836 | 51 | <0.001 |
| TC AT - TC AT | 13.3000 | 10.8739 | 1.5079 | 10.2727 | 16.3273 | 8.820 | 51 | <0.001 |
| HDL on 0 - HDL AT | -6.5538 | 12.5990 | 1.7472 | -10.0614 | -3.0463 | -3.751 | 51 | <0.001 |
| LDL on 0 - LDL on 61 | 8.4615 | 12.1908 | 1.6906 | 5.0676 | 11.8555 | 5.005 | 51 | <0.001 |
| Triglycerides BT - Triglycerides AT | 22.8000 | 22.6049 | 3.1347 | 16.5067 | 29.0933 | 7.273 | 51 | <0.001 |
| VLDL BT - VLDL AT | 5.3308 | 4.9871 | .6916 | 3.9424 | 6.7192 | 7.708 | 51 | <0.001 |

BT: Before Treatment, AT: After Treatment

Table 11: Paired Samples Test (Diet manipulation Group)

| | Paired Differences | | | | | t | df | Sig. (2-tailed) |
|----------------------|--------------------|----------------|-----------------|---|---------|--------|----|-----------------|
| | Mean | Std. Deviation | Std. Error Mean | 95% Confidence Interval of the Difference | | | | |
| | | | | Lower | Upper | | | |
| BMI BT – AT | 0.62620 | 0.68429 | 0.09677 | 0.43173 | 0.82067 | 6.471 | 49 | <0.001 |
| TC BT – AT | 8.6089 | 6.1940 | 0.9233 | 6.7480 | 10.4698 | 9.324 | 44 | <0.001 |
| HDL BT –AT | -0.8222 | 1.7902 | 0.2669 | -1.3601 | -.2844 | -3.081 | 44 | 0.004 (<0.05) |
| LDL BT –AT | 8.5742 | 8.5016 | 1.2673 | 6.0200 | 11.1284 | 6.765 | 44 | <0.001 |
| Triglycerides BT –AT | 10.1267 | 10.1412 | 1.5118 | 7.0799 | 13.1734 | 6.699 | 44 | <0.001 |
| VLDL BT –AT | 1.0778 | 2.4834 | 0.3702 | 0.3317 | 1.8239 | 2.911 | 44 | 0.006 (<0.05) |

BT: Before Treatment, AT: After Treatment

Table 12: Statistics between the Groups

| | Clinical Group | N | Mean | Std. Deviation | Std. Error Mean |
|---------|-----------------|----|---------|----------------|-----------------|
| BMI | Amalaki Choorna | 52 | -0.1469 | 0.2191 | 0.03038 |
| AT - BT | Diet control | 50 | -0.6262 | 0.68429 | 0.09677 |
| TC | Amalaki Choorna | 52 | -13.3 | 10.8739 | 1.5079 |
| AT - BT | Diet control | 50 | -8.82 | 6.6198 | 0.9362 |
| LDL | Amalaki Choorna | 52 | -8.415 | 12.1755 | 1.6884 |
| AT - BT | Diet control | 50 | -8.682 | 8.248 | 1.1664 |
| TGL | Amalaki Choorna | 52 | -21.808 | 23.5821 | 3.2703 |
| AT - BT | Diet control | 50 | -9.8 | 9.6976 | 1.3714 |
| HDL | Amalaki Choorna | 52 | 6.554 | 12.599 | 1.7472 |
| AT -BT | Diet control | 50 | 0.814 | 1.7628 | 0.2493 |
| VLDL | Amalaki Choorna | 52 | -5.173 | 5.1536 | 0.7147 |
| AT - BT | Diet control | 50 | -0.822 | 2.7569 | 0.3899 |

BT: Before Treatment, AT: After Treatment

Table 13: Independent Samples Test (between the groups)

| | t-test for Equality of Means | | | | | | |
|---------|------------------------------|-----|-----------------|-----------------|-----------------------|---|---------|
| | t | df | Sig. (2-tailed) | Mean Difference | Std. Error Difference | 95% Confidence Interval of the Difference | |
| | | | | | | Lower | Upper |
| BMI | 4.802 | 100 | <0.001 | 0.47928 | 0.09981 | 0.28126 | 0.67729 |
| AT - BT | | | | | | | |
| TC | -2.501 | 100 | 0.014 (<0.05) | -4.4800 | 1.7911 | -8.0335 | -0.9265 |
| AT - BT | | | | | | | |
| LDL | 0.129 | 100 | 0.898 | 0.2666 | 2.0673 | -3.8349 | 4.3681 |
| AT - BT | | | | | | | |
| TGL | -3.339 | 100 | 0.001 (<0.05) | -12.0077 | 3.5964 | -19.1429 | -4.8725 |
| AT - BT | | | | | | | |
| HDL | 3.191 | 100 | 0.002 (<0.05) | 5.7398 | 1.7988 | 2.1711 | 9.3086 |
| AT -BT | | | | | | | |
| VLDL | -5.286 | 100 | <0.001 | -4.3511 | 0.8231 | -5.9841 | -2.7180 |
| AT - BT | | | | | | | |

BT: Before Treatment, AT: After Treatment

DISCUSSION

The condition dyslipidemia has its pathophysiology that can be compared to ‘Shonitabhishyanda’ whose causes (Nidana) of can be of two groups i.e., Excessive and / or regular consumption of foods with Atisnigdha (excessively unctuous) – Pichchila (slimy)- Madhura (sweet) quality as well as excessive consumption of foods with Snigdha (unctuous)-Ushna (hot)-Vidahi (producing burning effects) properties. When these causes coupled with sedentary lifestyle will lead to Shonitabhishyanda i.e., Abhishyanda in blood (Rakta) caused by increased moisture level (Kledata) in blood.

The present study demonstrated the utility of Amalaki as a possible food supplement in dyslipidemia. Food (Ahara) is brings about its effect via its flavor (Rasa) and not by potency (Veerya)¹⁰. Amalaki is a fruit for daily consumption¹¹. When it comes to storage, powder is the safe and best form¹². This, when added to food as supplement, will have its mode of action similar to food. Hence, acts via it’s flavor rather its potency. Amalaki is highly appreciated as Rasayana i.e. once consumed

gives stability to all the dhatus; enhances quantity and quality of life¹³ and Vayasthapaka¹⁴ (anti aging). Such actions are well demonstrated by its cytoprotective and immunomodulating actions¹⁵. It can be well consumed any time before, during or after in relation to consumption of food without causing any disturbance in the level of Doshas¹⁶. It pacifies all the three doshas¹⁷. It has Lavana Varjita Pancha rasa (five flavours except salty); Sheeta (cold), Ruksha (causing dryness in body tissues) and Laghu (gets digested easily) Guna (qualities)¹⁸. Dyslipidemia demonstrates increased Apyamsha (liquidity) and Kledabhava (moisture) in Rakta. The break in pathology (Samprapti vighatana) takes place by the reduction in or managing apyamsha and kleda bhava in Rakta. Sneha guna is reduced by Ruksha guna of Amalaki; brings about Shoshana (causing dryness) action (reduces Apyamsha by its Ruksha guna). The presence of Tikta (bitter)-kashaya (Astringent) rasa dries up the moisture (Kledopashoshana) as well as pacifies both Kapha and Pitta; pacifies Rakta. The stability in serum level of lipids is brought about by its Rasayana (rejuvenating) action. The ill effects of the dyslipidemia (increased oxidative stress) are prevented by the Vayasthapana (antiaging) action.

It is a well known fruit for its anti-inflammatory action^{19, 20, 21} and hepato-protective action²². Amalaki is a well known antioxidant²³. The major chemical constituents of Amalaki (*Emblca officinalis Garten*) are Ascorbic acid, Gallic acid, Chebulinic acid, Chebulagic acid, Ellagic Acid, 3-ethyl gallic acid, corilagin, emblicanin A and B, Punigluconin, quercetin²⁴. It has phytosterols and saponins. Ascorbic acid (Vitamin C) is a dietary antioxidant, helping in reduction of oxidative stress²⁵. The fruits have 28% of the total tannins distributed in the whole plant. It contains two hydrolysable tannins Emblicanin A and B, which have antioxidant properties²⁶one on hydrolysis gives gallic acid, ellagic acid and glucose wherein the other gives ellagic acid and glucose. The fruit also contains Phyllembin. The active principles are tannins and Gallic acid²⁷. In the current study, Amalaki choorna when subjected to HPTLC revealed that it had Gallic acid, a product on hydrolysis of Emblicanin A. and that helps prevent oxidative stress leading to dyslipidemia It's HPTLC also revealed that there is Ascorbic acid (Vitamin C), a dietary antioxidant, helping in reduction of oxidative stress²⁸. The fruit yields good amount of dietary fibers. Dietary fibers are reported to increase the excretion of cholesterol by interfering with enterohepatic circulation of cholesterol^{29,30}. Phytosterols are known to inhibit cholesterol absorption from the intestine due to their greater hydrophobicity and greater affinity for micelles than cholesterol itself and displace the intestinal cholesterol³¹ Saponins are capable of precipitating cholesterol from micelles and interfere with enterohepatic circulation of bile acids, making them unavailable for intestinal absorption, leading to a reduction in plasma and hepatic cholesterol levels³². All these explain the significant result of Amalaki choorna as food supplement over the minimal diet manipulations.

CONCLUSION

Amalaki is a fruit for daily consumption that can be consumed in powder form added food as food supplement. The study concludes that administration of Amalaki Choorna (powder of *Emblca officinalis Garten*) is a possible food supplement of choice that manages dyslipidemia significantly without causing any adverse effects. It can also significantly manage weight. It can be tried in constipation and gastritis as a part of food adding it in powder form spreaded throughout the day. The other observations of study reveal that Dyslipidemia is an iceberg disease that is seen equally in both the genders. The younger age group (20-39 years) is at risk of having dyslipidemia. Sedentary lifestyle, overweight and obesity tend to put the subjects at risk of dyslipidemia. People with Kapha Vata Prakriti are at risk of having dyslipidemia when compared to others. Multiple lipid abnormality is a common pattern in dyslipidemia of which abnormal total cholesterol and triglycerides are commonest. Dyslipidemia does not exhibit any symptoms most of the time and hence is less reported. This proves it to be an iceberg condition. There is appreciable reduction in the sleeping hours which may influence on digestion mechanism, thereby influencing the lipid levels. Reduced time gap between food and sleep at night is prevailing practice might have an influence indirectly on the lipid metabolism.

REFERENCES

1. Shashank RJ et al. Prevalence of Dyslipidemia in Urban and Rural India: The ICMR-INDIAB Study. *PLoS One* 2014; 9(5):e96808.
2. U.S. Department of Health and Human Services. *What is a dietary supplement?*
3. Nilesh G, Bhavna S, Kruti P, Prateek P. Physicochemical And Antimicrobial Activity Of Single Herbal Formulation -

Capsule, Containing *Emblca officinalis* GAERTN.. *International Journal of Pharmacy and Pharmaceutical Sciences* 2011; 3(5):383-386.

4. Nikhil K S, Sudhir S G, Ranjana S, Yatindra K. An Investigation into Phytochemical Profile and Neutraceutical value of Amla (*Emblca officinalis*) Fruits . *Int J Mod Pharm Res* 2013; 2(1)
5. Agnivesha. *Caraka Samhita*, 1 ed. Varanasi: Chaukhamba Surbharati Prakashan; 2000.
6. Charaka, Chakrapani commentator . Matrashitiya Adhyaya. Acharya Y T (ed). *Charaka Samhita of Agnivesha*, 5 ed. Varanasi: Choukhambha Sanskrit Sansthan; 2003. pp. 38.
7. Sushruta. Annapana vidhi. Acharya Jadavji Trikamji, Acharya Ram Narayan (eds). *Sushruta Samhita with Nibandhasangraha commentary of Dalhana*. Varanasi: Chaukhamba Surbharati prakashan; 2003. pp. 463
8. Lipid profile. <https://labtestsonline.org> (accessed 1 March 2010)
9. Deng B, Luo T, Huang Y, Shen T, Ma J. Prevalence and determinants of hyperlipidemia in moderate altitude areas of the Yunnan-Kweichow plateau in Southwestern China.. *High Alt Med Biol* 2012; 13(1)
10. Agnivesha. Sutrasthana;Ch 2- Apamargatanduleeya; Verse 17; Commentary by Dalhana. Acharya JT (ed). *Charaka samhita of Agnivesha*, 5 ed. Varanasi: Choukhambha Prakashana; 2010. pp. 25.
11. Agnivesha . Ch.5 – Maatrashiteeya Verse 12. Acharya J T (ed). *Caraka Samhita of Agnivesa with Ayurveda-Dipika Commentary by Chakrapanidatta*, 5 ed. Varanasi: Chaukhambha Sanskrit Sansthan; 2001. pp. 38
12. MB Kavita, Mallika KJ. Amalaki (Indian gooseberry): An ancient food supplement. *Int. J. Res. Ayurveda Pharm.* 2013;4(1):11-14
13. Agnivesha. Chikitsasthana; ch. 1-Abayamalakeeyam Rasayanapadam;, Verse 145 . Acharya J T (ed). *Caraka Samhita of Agnivesa with Ayurveda-Dipika Commentary by Chakrapanidatta*, 5 ed. Varanasi: Chaukhambha Sanskrit Sansthan; 2001. pp.133
14. Agnivesha . Sutrasthana; chapter 25-Yajjahpurusheeya Adhyaya; Verse 40. Acharya J T (ed). *Caraka Samhita of Agnivesa with Ayurveda-Dipika Commentary by Chakrapanidatta*, 5 ed. Varanasi: Chaukhambha Sanskrit Sansthan; 2001. pp. 132.
15. M Sai Ram et al. Cyto-protective and immunomodulating properties of Amla (*Emblca officinalis*) on lymphocytes: an in-vitro study. *Journal of Ethnopharmacology* 2002; 81(1)
16. Sushruta. Sutrasthana; Ch 46 - Annapana Vidhi; Verse 463. Acharya YT, Acharya R N (eds). *Sushruta Samhita by Sushruta*, 1 ed. Varanasi: Choukhambha Surabharati Prakashan; 2002. pp. 227
17. Sushruta. Sutrasthana; Ch 46 - Annapana Vidhi; Verse 143-144. Acharya YT, Acharya R N (eds). *Sushruta Samhita by Sushruta*, 1 ed. Varanasi: Choukhambha Surabharati Prakashan; 2002. pp. 227
18. Agnivesha. Sutrasthana;Ch 27- Annapana Vidhi Adhyaya; Verse 147. Acharya YT (ed). *Charaka samhita of Agnivesha*, 5 ed. Varanasi: Choukhambha Sanskrit Sansthan; 2001. pp. 161
19. Arunachalam M, Shailja S, Sumeet KS . The antiinflammatory potential of phenolic compounds from *Emblca officinalis* L. in rat. *Inflammopharmacology* 2011; 19(6)
20. Eugeny AP et al. Chemical and antioxidant evaluation of Indian gooseberry (*Emblca officinalis* Gaertn., syn. *Phyllanthus emblica* L.) supplements. *Phytotherapy Research* 2009; 23(9)

21. Madhuri S, Pandey G, Verma KS. Antioxidant, Immunomodulatory and Anticancer activities of *Emblica officinalis*: An overview. *Int. Res. J. Pharm.* 2011; 2(8).
22. Anil UT, Sanjay JS, Manisha PS, and Nehal HG. Hepatoprotective effect of poly herbal formulation against various hepatotoxic agents in rats. *Pharmacognosy Research* 2012; 4(1).
23. Gupta Priya et al. Antimicrobial and Antioxidant Activity on *Emblica officinalis* seed extract. *Int. J. Res. Ayurveda Pharm.* 2012;3(4) :591-596
24. Neeraj T, Madhu S. *Quality Standards of Indian Medicinal Plants. Volume 8.* New Delhi: Indian Council of Medical Research; 2010.
25. Pankaj J, Ashutosh P, Yashumati R, Swapnil S, Sarvesh P. Free Radicals and Dietary Antioxidants. *International Journal of Pharmaceutical Sciences Review and research* 2013; 18(1)
26. Bhattacharya, A, Ghosal, S, Bhattacharya, SK. Antioxidant activity of tannoid principles of *Emblica officinalis* (amla) in chronic stress induced changes in rat brain.. *Indian Journal of Experimental Biology* 2000; 38()
27. *Emblica officinalis*. <http://thaiherbinfo.com> (accessed 5 August 2014).
28. Pankaj J, Ashutosh P, Yashumati R, Swapnil S, Sarvesh P. Free Radicals and Dietary Antioxidants: A Potential Review. *International Journal of Pharmaceutical Sciences Review and research* 2013; 18(1)
29. Moundras C, Behr SR, Remesy C, Demigne C. Fecal losses of sterols and bile acids induced by feeding rats guar gum are due to greater pool size and liver bile acid secretion. *The Journal of Nutrition* 1997; 127(6)
30. Arjmandi BH, Ahn J, Nathani S, Reeves RD. Dietary soluble fiber and cholesterol affect serum cholesterol concentration, hepatic portal venous short-chain fatty acid concentrations and fecal sterol excretion in rats. *Journal of Nutrition* 1992; 122(2)
31. Rupal A. Vasant, Narasimhacharya AVR. Alleviatory effects of *Emblica officinalis* g. as a food supplement in fluoride induced hyperlipemia and oxidative stress. *International Journal of Pharmacy and Pharmaceutical Sciences* 2012; 4(1)
32. Kritchevsky D, Chen SC. Phytosterols- health benefits and potential concerns: a review. *Nutrition Research* 2005; 25(5):413-428
33. Rancis G, Kerem Z, Makkar HPS, Becker K. The biological action of saponins in animal systems: a review. *British Journal of Nutrition* 2002; 88(6): 587-605

Cite this article as:

M. B. Kavita, Mallika KJ, Poornima B. A clinical study on effect of amalaki (Indian gooseberry) as food supplement in dyslipidemia. *Int. J. Res. Ayurveda Pharm.* Jul - Aug 2016;7(4):59-64 <http://dx.doi.org/10.7897/2277-4343.074134>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IJRAP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IJRAP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IJRAP editor or editorial board members.